Light on life: immunoscore immune-checkpoint, a predictor of immunotherapy response

References

• Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18(3):197–8. doi:10.1038/s41573-018-0007-y. PMID: 30610226.
   PubMed Web of Science ®Google Scholar
• Bruni D, Angell HK, Galon J. The immune contexture and immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer. 2020;20(11):662–680. doi:10.1038/s41568-020-0285-7. PMID: 32753728.
   PubMed Web of Science ®Google Scholar
• Kallingal A, Olszewski M, Maciejewska N, Brankiewicz W, Baginski M. Cancer immune escape: the role of antigen presentation machinery. J Cancer Res Clin Oncol. 2023;149(10):8131–8141. doi:10.1007/s00432-023-04737-8. PMID: 37031434.
   PubMed Web of Science ®Google Scholar
• Bindea G, Mlecnik B, Angell HK, Galon J. The immune landscape of human tumors: implications for cancer immunotherapy. Oncoimmunol. 2014;3(2):e27456. doi:10.4161/onci.27456. PMID: 24800163.
   PubMedGoogle Scholar
• Bindea G, Mlecnik B, Fridman WH, Galon J. The prognostic impact of anti-cancer immune response: a novel classification of cancer patients. Semin Immunopathol. 2011;33(4):335–340. doi:10.1007/s00281-011-0264-x. PMID: 21461991.
   PubMed Web of Science ®Google Scholar
• Mlecnik B, Bifulco C, Bindea G, Marliot F, Lugli A, Lee JJ, Zlobec I, Rau TT, Berger MD, Nagtegaal ID, et al. Multicenter international society for immunotherapy of cancer study of the consensus immunoscore for the prediction of survival and response to chemotherapy in stage III colon cancer. J Clin Oncol. 2020;38:3638–3651. doi:10.1200/jco.19.03205. PMID: 32897827.
   PubMed Web of Science ®Google Scholar
• Mlecnik B, Torigoe T, Bindea G, Popivanova B, Xu M, Fujita T, Hazama S, Suzuki N, Nagano H, Okuno K, et al. Clinical performance of the consensus immunoscore in colon cancer in the Asian population from the multicenter international SITC study. Cancers (Basel). 2022;14(18):4346. doi:10.3390/cancers14184346. PMID: 36139506.
   PubMed Web of Science ®Google Scholar
• Pagès F, André T, Taieb J, Vernerey D, Henriques J, Borg C, Marliot F, Ben Jannet R, Louvet C, Mineur L, et al. Prognostic and predictive value of the immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study. Ann Oncol. 2020;31(7):921–929. doi:10.1016/j.annonc.2020.03.310. PMID: 32294529.
   PubMed Web of Science ®Google Scholar
• Maby P, Galon J, Latouche JB. Frameshift mutations, neoantigens and tumor-specific CD8 + T cells in microsatellite unstable colorectal cancers. Oncoimmunol. 2016;5(5):e1115943. doi:10.1080/2162402X.2015.1115943. PMID: 27467916.
   PubMed Web of Science ®Google Scholar
• Maby P, Tougeron D, Hamieh M, Mlecnik B, Kora H, Bindea G, Angell HK, Fredriksen T, Elie N, Fauquembergue E, et al. Correlation between density of CD8+ T-cell infiltrate in microsatellite unstable colorectal cancers and frameshift mutations: a rationale for personalized immunotherapy. Cancer Res. 2015;75(17):3446–3455. doi:10.1158/0008-5472.CAN-14-3051. PMID: 26060019.
   PubMed Web of Science ®Google Scholar
• Mlecnik B, Bindea G, Angell HK, Maby P, Angelova M, Tougeron D, Church SE, Lafontaine L, Fischer M, Fredriksen T, et al. Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity. 2016;44(3):698–711. doi:10.1016/j.immuni.2016.02.025. PMID: 26982367.
   PubMed Web of Science ®Google Scholar
• Foucher ED, Ghigo C, Chouaib S, Galon J, Iovanna J, Olive D. Pancreatic ductal adenocarcinoma: a strong imbalance of good and bad immunological cops in the tumor microenvironment. Front Immunol. 2018;9:1044. doi:10.3389/fimmu.2018.01044. PMID: 29868007.
   PubMed Web of Science ®Google Scholar
• Dutta S, Ganguly A, Chatterjee K, Spada S, Mukherjee S. Targets of immune escape mechanisms in cancer: basis for development and evolution of cancer immune checkpoint inhibitors. Biology (Basel). 2023;12(2):218. doi:10.3390/biology12020218. PMID: 36829496.
   PubMedGoogle Scholar
• Aranda F, Vacchelli E, Obrist F, Eggermont A, Galon J, Sautes-Fridman C, Cremer I, Henrik Ter Meulen J, Zitvogel L, Kroemer G, et al. Trial watch: toll-like receptor agonists in oncological indications. Oncoimmunol. 2014;3(6):e29179. doi:10.4161/onci.29179. PMID: 25083332.
   PubMed Web of Science ®Google Scholar
• Bloy N, Buqué A, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautès-Fridman C, Fucikova J, Galon J, Spisek R, et al. Trial watch: naked and vectored DNA-based anticancer vaccines. Oncoimmunol. 2015;4(5):e1026531. doi:10.1080/2162402x.2015.1026531. PMID: 26155408.
   PubMed Web of Science ®Google Scholar
• Buque A, Bloy N, Aranda F, Castoldi F, Eggermont A, Cremer I, Fridman WH, Fucikova J, Galon J, Marabelle A, et al. Trial watch: immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunol. 2015;4(4):e1008814. doi:10.1080/2162402X.2015.1008814. PMID: 26137403.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautes-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial watch: adoptive cell transfer immunotherapy. Oncoimmunol. 2012;1(3):306–315. doi:10.4161/onci.19549. PMID: 22737606.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vacchelli E, Fridman WH, Galon J, Sautes-Fridman C, Tartour E, Zucman-Rossi J, Zitvogel L, Kroemer G. Trial watch: monoclonal antibodies in cancer therapy. Oncoimmunol. 2012;1(1):28–37. doi:10.4161/onci.1.1.17938. PMID: 22720209.
   PubMed Web of Science ®Google Scholar
• Iribarren K, Bloy N, Buqué A, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Špíšek R, Zitvogel L, et al. Trial watch: immunostimulation with toll-like receptor agonists in cancer therapy. Oncoimmunol. 2016;5(3):e1088631. doi:10.1080/2162402x.2015.1088631. PMID: 27141345.
   PubMed Web of Science ®Google Scholar
• Pol J, Bloy N, Buque A, Eggermont A, Cremer I, Sautes-Fridman C, Galon J, Tartour E, Zitvogel L, Kroemer G, et al. Trial watch: peptide-based anticancer vaccines. Oncoimmunol. 2015;4(4):e974411. doi:10.4161/2162402X.2014.974411. PMID: 26137405.
   PubMed Web of Science ®Google Scholar
• Pol J, Buqué A, Aranda F, Bloy N, Cremer I, Eggermont A, Erbs P, Fucikova J, Galon J, Limacher JM, et al. Trial watch—oncolytic viruses and cancer therapy. Oncoimmunol. 2016;5(2):e1117740. doi:10.1080/2162402x.2015.1117740. PMID: 27057469.
   PubMed Web of Science ®Google Scholar
• Senovilla L, Vacchelli E, Garcia P, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: DNA vaccines for cancer therapy. Oncoimmunol. 2013;2(4):e23803. doi:10.4161/onci.23803. PMID: 23734328.
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Aranda F, Bloy N, Buqué A, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Spisek R, et al. Trial watch—immunostimulation with cytokines in cancer therapy. Oncoimmunol. 2016;5(2):e1115942. doi:10.1080/2162402x.2015.1115942. PMID: 27057468.
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Aranda F, Obrist F, Eggermont A, Galon J, Cremer I, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: immunostimulatory cytokines in cancer therapy. Oncoimmunol. 2014;3(6):e29030. doi:10.4161/onci.29030. PMID: 25083328.
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Bloy N, Aranda F, Buqué A, Cremer I, Demaria S, Eggermont A, Formenti SC, Fridman WH, Fucikova J, et al. Trial watch: immunotherapy plus radiation therapy for oncological indications. Oncoimmunol. 2016;5(9):e1214790. doi:10.1080/2162402x.2016.1214790. PMID: 27757313.
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Eggermont A, Galon J, Sautes-Fridman C, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: monoclonal antibodies in cancer therapy. Oncoimmunol. 2013;2(1):e22789. doi:10.4161/onci.22789. PMID: 23482847.
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Galluzzi L, Eggermont A, Galon J, Tartour E, Zitvogel L, Kroemer G. Trial watch: immunostimulatory cytokines. Oncoimmunol. 2012;1(4):493–506. doi:10.4161/onci.20459. PMID: 22754768.
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Galluzzi L, Fridman WH, Galon J, Sautes-Fridman C, Tartour E, Kroemer G. Trial watch: chemotherapy with immunogenic cell death inducers. Oncoimmunol. 2012;1(2):179–188. doi:10.4161/onci.1.2.19026. PMID: 22720239.
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Martins I, Eggermont A, Fridman WH, Galon J, Sautes-Fridman C, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: peptide vaccines in cancer therapy. Oncoimmunol. 2012;1(9):1557–1576. doi:10.4161/onci.22428. PMID: 23264902.
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Senovilla L, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: chemotherapy with immunogenic cell death inducers. Oncoimmunol. 2013;2(3):e23510. doi:10.4161/onci.23510. PMID: 23687621.
   PubMed Web of Science ®Google Scholar
• Church SE, Galon J. Tumor microenvironment and immunotherapy: the whole picture is better than a glimpse. Immunity. 2015;43(4):631–633. doi:10.1016/j.immuni.2015.10.004. PMID: 26488814.
   PubMed Web of Science ®Google Scholar
• Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers (Basel). 2020;12(3):738. doi:10.3390/cancers12030738. PMID: 32245016.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Capone M, Urba WJ, Bifulco CB, Botti G, Lugli A, Marincola FM, Ciliberto G, Galon J, Fox BA. The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. J Transl Med. 2013;11(1):54. doi:10.1186/1479-5876-11-54. PMID: 23452415.
   PubMedGoogle Scholar
• Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–571. doi:10.1038/nature13954. PMID: 25428505.
   PubMed Web of Science ®Google Scholar
• Wang R, Lian J, Wang X, Pang X, Xu B, Tang S, Shao J, Lu H. Intrinsic resistance and efficacy of immunotherapy in microsatellite instability-high colorectal cancer: a systematic review and meta-analysis. Biomol Biomed. 2023;23(2):198–208. doi:10.17305/bjbms.2022.8286. PMID: 36408953.
   PubMedGoogle Scholar
• Bindea G, Mlecnik B, Galon J. Expand to shield: IL-15 and in situ lymphocytic proliferation. Oncoimmunol. 2021;10(1):1886726. doi:10.1080/2162402X.2021.1886726. PMID: 33628626.
   PubMed Web of Science ®Google Scholar
• Mlecnik B, Tosolini M, Charoentong P, Kirilovsky A, Bindea G, Berger A, Camus M, Gillard M, Bruneval P, Fridman WH, et al. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterol. 2010;138(4):1429–1440. doi:10.1053/j.gastro.2009.10.057. PMID: 19909745.
   PubMed Web of Science ®Google Scholar
• Voabil P, de Bruijn M, Roelofsen LM, Hendriks SH, Brokamp S, van den Braber M, Broeks A, Sanders J, Herzig P, Zippelius A, et al. An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer. Nat Med. 2021;27(7):1250–1261. doi:10.1038/s41591-021-01398-3. PMID: 34239134.
   PubMed Web of Science ®Google Scholar
• Limagne E, Nuttin L, Thibaudin M, Jacquin E, Aucagne R, Bon M, Revy S, Barnestein R, Ballot E, Truntzer C, et al. MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells. Cancer Cell. 2022;40(2):136–152.e12. doi:10.1016/j.ccell.2021.12.009. PMID: 35051357.
   PubMed Web of Science ®Google Scholar
• Danaher P, Warren S, Lu RZ, Samayoa J, Sullivan A, Pekker I, Wallden B, Marincola FM, Cesano A. Pan-cancer adaptive immune resistance as defined by the tumor inflammation signature (TIS): results from the cancer genome atlas (TCGA). J Immunotherapy Cancer. 2018;6(1). doi:10.1186/s40425-018-0367-1. PMID: 29929551.
   PubMedGoogle Scholar
• Galon J, Sudarshan C, Ito S, Finbloom D, O’Shea JJ. IL-12 induces IFN regulating factor-1 (IRF-1) gene expression in human NK and T cells. J Immunol. 1999;162(12):7256–7262. doi:10.4049/jimmunol.162.12.7256. PMID: 10358173.
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Bibeau F, Greillier L, Fumet JD, Ilie A, Monville F, Lauge C, Catteau A, Boquet I, Majdi A, et al. Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancer. EBioMedicine. 2023;92:104633. doi:10.1016/j.ebiom.2023.104633. PMID: 37244159.
   PubMed Web of Science ®Google Scholar
• Patel A, Balis UGJ, Cheng J, Li Z, Lujan G, McClintock DS, Pantanowitz L, Parwani A. Contemporary whole slide imaging devices and their applications within the modern pathology department: a selected hardware review. J Pathol Inform. 2021;12(1):50. doi:10.4103/jpi.jpi_66_21. PMID: 35070479.
   PubMedGoogle Scholar
• Antoniotti C, Rossini D, Pietrantonio F, Catteau A, Salvatore L, Lonardi S, Boquet I, Tamberi S, Marmorino F, Moretto R, et al. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 2022;23(7):876–887. doi:10.1016/S1470-2045(22)00274-1. PMID: 35636444.
   PubMed Web of Science ®Google Scholar
• Gandini A, Puglisi S, Pirrone C, Martelli V, Catalano F, Nardin S, Seeber A, Puccini A, Sciallero S. The role of immunotherapy in microsatellites stable metastatic colorectal cancer: state of the art and future perspectives. Front Oncol. 2023;13:1161048. doi:10.3389/fonc.2023.1161048. PMID: 37207140.
   PubMed Web of Science ®Google Scholar
• Grothey A, Tabernero J, Arnold D, De Gramont A, Ducreux MP, O’Dwyer PJ, Van Cutsem E, Bosanac I, Srock S, Mancao C, et al. Fluoropyrimidine (FP) plus bevacizumab (BEV) plus atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): findings from cohort 2 of MODUL - a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy. Ann Oncol 2018;29(S8): viii714–viii715. PMID: WOS:000459277304376.
   Google Scholar
• Mettu NB, Ou FS, Zemla TJ, Halfdanarson TR, Lenz HJ, Breakstone RA, Boland PM, Crysler OV, Wu C, Nixon AB, et al. Assessment of capecitabine and bevacizumab with or without atezolizumab for the treatment of refractory metastatic colorectal cancer a randomized clinical trial. JAMA Netw Open. 2022;5(2):e2149040. doi:10.1001/jamanetworkopen.2021.49040. PMID: WOS:000757514300012.
   PubMed Web of Science ®Google Scholar
• Lenz HJ, Parikh AR, Spigel DR, Cohn AL, Yoshino T, Kochenderfer MD, Elez E, Shao SH, Deming DA, Holdridge RC, et al. Nivolumab (NIVO)+5-fluorouracil/leucovorin/oxaliplatin (mFOLFOX6)/bevacizumab (BEV) versus mFOLFOX6/BEV for first-line (1L) treatment of metastatic colorectal cancer (mCRC): phase 2 results from CheckMate 9X8. JCO. 2022;40(4_suppl):8–8. doi:10.1200/JCO.2022.40.4_suppl.008. PMID: WOS:000770995900009.
   PubMed Web of Science ®Google Scholar
• Antoniotti C, Boccaccino A, Seitz R, Giordano M, Catteau A, Rossini D, Pietrantonio F, Salvatore L, McGregor K, Bergamo F, et al. An immune-related gene expression signature predicts benefit from adding atezolizumab to FOLFOXIRI plus bevacizumab in metastatic colorectal cancer. Clin Cancer Res. 2023;29(12):2291–2298. doi:10.1158/1078-0432.CCR-22-3878. PMID: 37022350.
   PubMed Web of Science ®Google Scholar
• Moretto R, Rossini D, Catteau A, Antoniotti C, Giordano M, Boccaccino A, Ugolini C, Proietti A, Conca V, Kassambara A, et al. Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study. J Immunother Cancer. 2023;11(4):e006633. doi:10.1136/jitc-2022-006633. PMID: 37085190.
   PubMed Web of Science ®Google Scholar
• Angell HK, Bruni D, Barrett JC, Herbst R, Galon J. The immunoscore: colon cancer and beyond. Clin Cancer Res. 2020;26(2):332–339. doi:10.1158/1078-0432.ccr-18-1851. PMID: 31413009.
   PubMed Web of Science ®Google Scholar
• Galon J, Bruni D. Tumor immunology and tumor evolution: intertwined histories. Immunity. 2020;52(1):55–81. doi:10.1016/j.immuni.2019.12.018. PMID: 31940273.
   PubMed Web of Science ®Google Scholar
• Pages F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, Lugli A, Zlobec I, Rau TT, Berger MD, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391(10135):2128–2139. doi:10.1016/S0140-6736(18)30789-X. PMID: 29754777.
   PubMed Web of Science ®Google Scholar
• Teng MW, Ngiow SF, Ribas A, Smyth MJ. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res. 2015;75(11):2139–2145. doi:10.1158/0008-5472.CAN-15-0255. PMID: 25977340.
   PubMed Web of Science ®Google Scholar
• Moore DC, Guinigundo AS. The role of biomarkers in guiding clinical decision-making in oncology. JADPRO. 2023;14(3):15–37. doi:10.6004/jadpro.2023.14.3.17. PMID: 37206905.
   Google Scholar